TY - JOUR. T1 - Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning. T2 - The effect of postgrafting mycophenolate mofetil dosing. AU - Maris, Michael B.. AU - Sandmaier, Brenda M.. AU - Storer, Barry E.. AU - Maloney, David G.. AU - Shizuru, Judith A.. AU - Agura, Edward. AU - Kliem, Constanze. AU - Pulsipher, Michael. AU - Maziarz, Richard T.. AU - McSweeney, Peter A.. AU - Wade, James. AU - Langston, Amelia A.. AU - Chauncey, Thomas R.. AU - Bruno, Benedetto. AU - Blume, Karl G.. AU - Storb, Rainer. PY - 2006/4/1. Y1 - 2006/4/1. N2 - We previously reported results in 71 patients with advanced hematologic malignancies given HLA-matched unrelated granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell (G-PBMC) grafts after fludarabine 90 mg/m2, 2 Gy of total body irradiation, and postgrafting mycophenolate mofetil (MMF) 15 mg/kg twice daily and cyclosporine 6.25 mg/kg ...
Blood, 2001; 98 (12) doi:. Authors: Zaucha J M, Gooley T, Bensinger W I, Heimfeld S, Chauncey T R Zaucha J M, Gooley T, Bensinger W I, Heimfeld S, Chauncey T R, Zaucha R, Martin P J, Flowers M E, Storek J, Georges G, Storb R, Torok-Storb B et al.(7) Affiliation: Fred Hutchinson Cancer Research Center, United States Abstract: A retrospective analysis of granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood mononuclear cell (G-PBMC) products harvested from healthy donors indicates significant variability in both the absolute number and relative proportion of CD34, CD3, and CD14 cells obtained. This report examined whether variations in the cellular composition of G-PBMC products correlated with clinical outcomes after myeloablative allogeneic transplantation. The numbers of CD34, CD3, and CD14 cells infused into 181 human leukocyte antigen (HLA)-identical sibling recipients were analyzed with respect to tempo of engraftment, acute graft-versus-host-disease (GVHD), clinical ...
Study Objective: To determine whether recombinant human granulocyte colony-stimulating factor (G-CSF) is effective in increasing neutrophil counts in patients with hairy cell leukemia and neutropenia.. Design: Open label, phase I/II study of G-CSF, given by daily subcutaneous injection for up to 7 weeks.. Setting: Outpatient oncology clinic of a university medical center.. Patients: A consecutive sample of four patients with hairy cell leukemia complicated by severe neutropenia. Three patients completed the study; one patient was removed after 2 weeks of therapy.. Interventions: Granulocyte colony-stimulating factor was given by daily subcutaneous injection. Each patient began therapy with 1 µg/kg body weight ·d; after 1 week the dose was increased to 3 µg/kg ·d, and 1 week later to 6 µg/ kg ·d. Therapy was continued for 5 to 6 weeks. Patients were taught self-injection, and administered treatment at home.. Measurements and main results: In three patients, an increase in absolute ...
TY - JOUR. T1 - Proteolytic enzyme levels are increased during granulocyte colony-stimulating factor-induced hematopoietic stem cell mobilization in human donors but do not predict the number of mobilized stem cells. AU - Van Os, R. AU - Van Schie, MLJ. AU - Willemze, R. AU - Fibbe, WE. PY - 2004/7. Y1 - 2004/7. N2 - Previous studies from our laboratory indicate that functional, mature neutrophils are essential for interleukin-8 (IL-8)-induced stem cell mobilization. To study a possible role of neutrophils in granulocyte colony-stimulating factor (G-CSF) induced hematopoietic mobilization, we assessed the number of circulating CD34(+) cells in healthy allogeneic stem cell donors on days 3, 4, and 5 of mobilization for comparison with the number of peripheral blood neutrophils and the plasma levels of IL-8, Flt3 ligand (FL), matrix metalloproteinase-9 (MMP-9), and human neutrophil elastase (HNE). Thirty-seven of 45 donors required 1 day of apheresis to obtain 5 x 10(6) CD34(+)/kg recipient body ...
Bioassay of Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF) for Neutropenia Treatment in Male Sprague Dawley Rats
Dragon Pharmaceutical announced to in-license the exclusive right to commercialize its Recombinant Human Granulocyte Colony Stimulating Factor.
Importance: Currently the gold standard treatment for ambulant patients is corticosteroids. Granulocyte colony-stimulating factor (G-CSF) has been reported to exert the proliferation of satellite cells, the regulation of myoblast proliferation, and the differentiation and promotion of muscle regeneration and repair.. Objectives To evaluate the safety and efficacy of G-CSF in children and adolescents with muscular dystrophies Duchenne muscular dystrophy, Becker muscular dystrophy , Fascioscapulohumeral dystrophy.. Design, Setting, and Participants: Patients aged 5-15 with diagnosed muscular dystrophies will be included in an open study. Patients wheelchair-bound and and mobile and self-independent can participate in the study. Patients also treated with steroids can participate in this study. Clinical examination and physiotherapeutic and laboratory tests will be perform. G-CSF (5mcg/kg/body/d) is given subcutaneously for five consecutive days during the 1st, 2nd, 3rd. 6th and 12th months. Blood ...
Importance: Currently the gold standard treatment for ambulant patients is corticosteroids. Granulocyte colony-stimulating factor (G-CSF) has been reported to exert the proliferation of satellite cells, the regulation of myoblast proliferation, and the differentiation and promotion of muscle regeneration and repair.. Objectives To evaluate the safety and efficacy of G-CSF in children and adolescents with muscular dystrophies Duchenne muscular dystrophy, Becker muscular dystrophy , Fascioscapulohumeral dystrophy.. Design, Setting, and Participants: Patients aged 5-15 with diagnosed muscular dystrophies will be included in an open study. Patients wheelchair-bound and and mobile and self-independent can participate in the study. Patients also treated with steroids can participate in this study. Clinical examination and physiotherapeutic and laboratory tests will be perform. G-CSF (5mcg/kg/body/d) is given subcutaneously for five consecutive days during the 1st, 2nd, 3rd. 6th and 12th months. Blood ...
BACKGROUND AND OBJECTIVE: Anemia leading to transfusion is probably the most important problem in patients with myelodysplastic syndromes (MDS). Human recombinant erythropoietin (rHuEpo) and granulocyte colony-stimulating factor (G-CSF) have been used to treat patients with anemia of MDS, but fewer than 50% respond. The aim of this work was to evaluate the benefit of rHuEpo +/- G-CSF treatment and to isolate the response predictive variables in a group of selected patients with MDS. DESIGN AND METHODS: A non-randomized multicenter trial was carried out in 32 patients with MDS. The inclusion criteria were age ,= 18 years, refractory anemia (RA) or refractory anemia with ringed sideroblasts, Hb ,= 100 g/L or receiving transfusions and serum erythropoietin ,= 250 U/L. These patients were treated with subcutaneous rHuEpo (300 U/kg) three times a week for 8 weeks. In the case of partial response (PR) or no response (NR) subcutaneosly administered G-CSF (1 microg/kg) three times a week was added to ...
The mortality rate at eight weeks was similar in the lenograstim and placebo groups (23 and 27 percent, respectively; P = 0.60), as was the incidence of severe infections. The median duration of neutropenia (absolute neutrophil count , or = 1000 per cubic millimeter) was shorter in the lenograstim group (21 days, as compared with 27 days in the placebo group; P , 0.001). Eight percent of the patients in both groups had regrowth of AML cells. The rate of complete remission was significantly higher in the lenograstim group (70 percent, as compared with 47 percent in the placebo group; P = 0.002). Overall survival, however, was similar in the two groups (P = 0.76). Conclusions: ...
TY - JOUR. T1 - Granulocyte colony-stimulating factor (G-GSF) prevents dose-limiting neutropenia in lymphoma patients receiving standard dose chemotherapy. AU - Dotti, G.. AU - Carlo Stella, C.. AU - Mangoni, L.. AU - Cottafavi, L.. AU - Caramatti, C.. AU - Almici, C.. AU - Rizzoli, V.. PY - 1995. Y1 - 1995. N2 - In this study, nine patients with non-Hodgkins lymphoma (n=6) and Hodgkins disease (n=3) receiving different cytotoxic chemotherapy regimens were given granulocyte colony-stimulating factor (C-CSF) (5 μg/kg/day) from 48 hours after the end of chemotherapy to 48 hours before the next chemotherapy administration. The decrease in mean absolute neutrophil counts (ANC) and in mean platelet (Plt) counts was not significant when pre-therapy counts were compared with posttherapy ones (p ,0.375 and p , 0.4, respectively). The mean actual dose intensity was 92% (range 68-100%). G-CSF treatment after chemotherapy reduces neutropenia and permits administration of the full chemotherapy program. A ...
TY - JOUR. T1 - A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor. AU - Schiller, J. H.. AU - Storer, B.. AU - Tutsch, K.. AU - Arzoomanian, R.. AU - Alberti, D.. AU - Feierabend, C.. AU - Spriggs, D.. PY - 1994/11/3. Y1 - 1994/11/3. N2 - Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), a novel antitubulin agent derived from the bark of the Pacific yew tree, may be one of the most active single agents in our chemotherapy armamentarium. Concern over acute hypersensitivity reactions has resulted in an administration schedule consisting of a 24-hour infusion. We conducted a phase I trial of a 3-hour infusion of paclitaxel to determine whether a 3-hour infusion could be administered with relative safety, and to identify the maximal tolerated dose with and without granulocyte colony-stimulating factor (G-CSF) support. Thirty-five patients with advanced, untreatable malignancies received a 3- hour infusion of paclitaxel once ...
Alzheimers disease (AD) is widely recognized as a serious public health problem and heavy financial burden. Currently, there is no treatment that can delay or stop the progressive brain damage in AD. Recently, we demonstrated that stem cell factor (SCF) in combination with granulocyte colony-stimulating factor (G-CSF) (SCF+G-CSF) has therapeutic effects on chronic stroke. The purpose of the present study is to determine whether SCF+G-CSF can reduce the burden of β-amyloid deposits in a mouse model of AD. APP/PS1 transgenic mice were used as the model of AD. To track bone marrow-derived cells in the brain, the bone marrow of the APP/PS1 mice was replaced with the bone marrow from mice expressing green fluorescent protein (GFP). Six weeks after bone marrow transplantation, mice were randomly divided into a saline control group and a SCF+G-CSF-treated group. SCF in combination with G-CSF was administered subcutaneously for 12 days. Circulating bone marrow stem cells (CD117+ cells) were quantified 1 day
OBJECTIVES: To estimate the cord blood levels of granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) in preterm infants and to study the relationship of these levels to pregnancy-induced hypertension (PIH) and absolute neutrophil counts.. STUDY DESIGN: G-CSF and GM-CSF levels in the cord blood of preterm neonates (n = 74) either with or without maternal PIH were estimated by enzyme-linked immunosorbent assay.. RESULTS: Infants in the PIH group had lower white blood cell, absolute neutrophil, absolute lymphocyte, and monocyte counts. The levels of G-CSF in cord blood were significantly lower in infants whose mothers had PIH (P =.04) and in infants with neutropenia (P =. 01). G-CSF levels were positively correlated with both absolute neutrophil count (P =.02) and total white blood cell count (P =.01). GM-CSF was undetectable in all subjects. According to logistic regression with neutropenia as the dependent variable, only maternal PIH (P ...
Our preliminary results suggest the existence of quantitative and qualitative differences in immune cells and type1 and type2 cytokines between granulocyte colony-stimulating factor (G-CSF) primed bone marrow (G-BM) and G-CSF-mobilized peripheral blood grafts (G-PB). Our findings suggest that lower T-cell hyporesponsiveness and easier polarization of T cells from Th1 to Th2 are found in G-BM. ...
Product Name: Mouse mAb anti- human Granulocyte Colony Stimulating Factor Receptor (G-CSFR), Clone S-1268Collection: AntibodySub Category: Monoclonal
Bone marrow mononuclear cell (BMMC) transplantation is a promising therapy for cerebral ischemia; however, little is known if its therapeutic efficacy may be improved by co-administration of potential modulatory factors in vivo. To explore this possibility, the present study examined the effect of BMMCs and G-CSF on cell proliferation, early neuronal development and neurological function recovery in experimental cerebral ischemia relative to controls that received neither treatment. Ischemia/infarct area was significantly reduced in BMMCs+G-CSF group relative to animal groups treated with BMMCs only, G-CSF only or saline. Transplanted BMMCs were found to colocalize with the proliferative cell nuclear antigen (PCNA) and the immature neuronal marker doublecortin (DCX). The BMMCs+G-CSF group showed increased numerical density of cells expressing PCNA and DCX, improved performance in adhesive sticker removal test and reduced neurological function severity scores relative to other groups in a time-dependent
Bone marrow mononuclear cell (BMMC) transplantation is a promising therapy for cerebral ischemia; however, little is known if its therapeutic efficacy may be improved by co-administration of potential modulatory factors in vivo. To explore this possibility, the present study examined the effect of BMMCs and G-CSF on cell proliferation, early neuronal development and neurological function recovery in experimental cerebral ischemia relative to controls that received neither treatment. Ischemia/infarct area was significantly reduced in BMMCs+G-CSF group relative to animal groups treated with BMMCs only, G-CSF only or saline. Transplanted BMMCs were found to colocalize with the proliferative cell nuclear antigen (PCNA) and the immature neuronal marker doublecortin (DCX). The BMMCs+G-CSF group showed increased numerical density of cells expressing PCNA and DCX, improved performance in adhesive sticker removal test and reduced neurological function severity scores relative to other groups in a time-dependent
TY - JOUR. T1 - Phase I study of simultaneous dose escalation and schedule acceleration of cyclophosphamide-doxoruhicin-etoposide using granulocyte colony-stimulating factor with or without antimicrobial prophylaxis in patients with small-cell lung cancer. AU - Ardizzoni, A.. AU - Pennucci, M. C.. AU - Danova, M.. AU - Viscoli, C.. AU - Mariani, G. L.. AU - Giorgi, G.. AU - Venturini, M.. AU - Mereu, C.. AU - Scolaro, T.. AU - Rosso, R.. PY - 1996. Y1 - 1996. N2 - A phase I study was designed to assess whether dose intensity of an accelerated cyclophosphamide- doxorubicin- etoposide (CDE) regimen plus granulocyte colony-stimulating factor (G-CSF) could be increased further, in an outpatient setting, by escalating the dose of each single drug of the regimen. Patients with previously untreated small-cell lung cancer (SCLC) received escalating doses of cyclophosphamide (C) 1100-1300 mg m-2 intravenously (i.v.) on day I, doxorubicin (D) 50-60 mg m-2 i.v. on day 1, etoposide (E) 110-130 mg m-2 i.v. ...
Gentaur molecular products has all kinds of products like :search , Prospecbio \ Mouse Anti Human Granulocyte Colony Stimulating Factor Biotin \ ANT-240 for more molecular products just contact us
The recombinant human G-CSF (rhG-CSF) synthesised in an E. coli expression system is called filgrastim. The structure of filgrastim differs slightly from the structure of the natural glycoprotein. Most published studies have used filgrastim. Filgrastim was first marketed by Amgen with the brand name Neupogen. Several bio-generic versions are now also available in markets such as Europe and Australia. Filgrastim (Neupogen) and PEG-filgrastim (Neulasta) are two commercially available forms of rhG-CSF. The PEG (polyethylene glycol) form has a much longer half-life, reducing the necessity of daily injections. Another form of rhG-CSF called lenograstim is synthesised in Chinese Hamster Ovary cells (CHO cells). As this is a mammalian cell expression system, lenograstim is indistinguishable from the 174-amino acid natural human G-CSF. No clinical or therapeutic consequences of the differences between filgrastim and lenograstim have yet been identified, but there are no formal comparative studies. ...
Granulocyte colony-stimulating factor (G-CSF) is the major regulator of granulopoiesis and acts through binding to its specific receptor (G-CSF-R) on neutrophilic granulocytes. Previous studies of signaling from the 4 G-CSF-R cytoplasmic tyrosine residues used model cell lines that may have idiosyncratic, nonphysiological responses. This study aimed to identify specific signals transmitted by the receptor tyrosine residues in primary myeloid cells. To bypass the presence of endogenous G-CSF-R, a chimeric receptor containing the extracellular domain of the epidermal growth factor receptor in place of the entire extracellular domain of the G-CSF-R was used. A series of chimeric receptors containing tyrosine mutations to phenylalanine, either individually or collectively, was constructed and expressed in primary bone marrow cells from G-CSF-deficient mice. Proliferation and differentiation responses of receptor-expressing bone marrow cells stimulated by epidermal growth factor were measured. An ...
SkyePharma is developing a formulation of granulocyte colony-stimulating factor (GCSF) for the prevention and treatment of chemotherapy-induced neutropenia.The
Background: Recent studies have shown that bone marrow mesenchymal stem cells (BMSCs) have a putative ability to promote neurogenesis and produce behavioral and functional improvement. Our previous study demonstrated that co-treatment of granulocyte colony-stimulating factor (G-CSF) and BMSCs have beneficial effects on Parkinson's models. The main purpose of this research was ...
Buy our Recombinant human G-CSF protein. Ab9692 is an active full length protein produced in Escherichia coli and has been validated in FuncS, SDS-PAGE. Abcam…
Buy our Recombinant Human G-CSF protein. Ab54137 is a protein fragment produced in Escherichia coli and has been validated in SDS-PAGE. Abcam provides free…
CSPC Pharma is developing pegfilgrastim (PEG-rhG-CSF), a pegylated recombinant granulocyte colony-stimulating factor receptor agonist, for the prevention of
Cytokine regulation of prethymic T-lymphoid progenitor-cell proliferation and/or differentiation has not been well-defined, although much is known of cytokine regulation of hemopoietic stem- and progenitor-cell development. Here we use a recently identified hemopoietic growth factor, stem-cell factor (SCF) (a form of the c-kit ligand), and a transplant model of thymocyte regeneration to assess the effect of SCF on the in vivo generation of prethymic, thymocyte progenitor-cell activity. We show that recombinant rat SCF (rrSCF164) administered to weanling rats selectively induces an increase in thymocyte progenitor activity in the spleens of treated rats as compared to rats treated with vehicle, polyethylene glycol (PEG)-conjugated rat albumin, or recombinant human granulocyte colony-stimulating factor (rhG-CSF). These data demonstrate that administration of SCF in vivo affects extrathymic-origin thymocyte regenerating cells and may influence, directly or indirectly, early prethymic stages of T-cell
cost. 2 Prophylactic use of recombinant human granulocyte colony-stimulating factors (G-CSFs), such as filgrastim or pegfilgrastim, can significantly reduce FN risk and FN-related costs. 3 - 5 The risk of developing FN depends on patient and disease. ...
Introduction: Naturally occurring antibodies (auto-Abs) recognizing human granulocyte-colony stimulating factor were detected with high frequency in serum samples obtained from umbilical cord blood of newborns (12 of 65 samples screened) and maternal peripheral blood serum samples from women at the end of gestation (seven of 56 cases tested). The aim of this paper was to demonstrate that auto-Abs anti-G-CSF revealed in the blood of newborns were produced during foetal life. Materials and methods: Mononuclear cells from cord blood samples of different newborns containing high titer anti-G-CSF Abs were infected with Epstein-Barr virus in vitro, and EBV-immortalized B-cell lines were isolated and characterized for specific anti-G-CSF Ab production. Results: Six different, unrelated cell lines of male origin which showed the presence of EBNA-2 antigen in the nucleus, displayed a B-cell phenotype (CD30+, CD5-, CD10-, HLA-DR+, CD19+, CD20+, CD23+, CD38+, CD25+), coexpressed low intensity sIgM and ...
The results of the present study demonstrate that G-CSF is neuroprotective in vitro (nearly complete protection) and displays a significant (47%) infarct-reducing effect after stroke and after intravenous administration. Neurons in the periphery of the infarction but also on the contralateral side exhibited specific binding of G-CSFR antiserum, indicative of a G-CSFR. Because the presence of G-CSFR on neurons is novel, we verified this finding by Western blot and RT-PCR. Furthermore, STAT3 expression was significantly increased in neurons of the penumbra in G-CSF-treated animals compared with control animals, suggesting an increased sensitivity to G-CSF. There was no effect on CBF as measured by LDF when both groups were compared. There were no significant differences in physiological parameters or in weight decline between both groups during the experiment. Mortality rate was significantly improved in animals treated with G-CSF compared with control animals. Neutrophilic blood count was ...
Human granulocyte colony stimulating factor (G-CSF) and macrophage colony stimulating factor (M-CSF) were administered intravenously to rats, and their effects on neutrophils and monocytes were...
Peripheral blood stem cells (PBSC) obtained from granulocyte-colony stimulating factor (G-CSF)-mobilized donors are increasingly used for allogeneic transplantation. Despite a 10-fold higher dose of transplanted T cells, acute graft-versus-host disease (GVHD) does not develop in higher proportion in recipients of PBSC than in recipients of marrow. T cells from G-CSF-treated experimental animals preferentially produce IL-4 and IL-10, cytokines characteristic of Th2 responses, which are associated with diminished GVHD-inducing ability. We hypothesized that G-CSF-mobilized PBSC contain antigen-presenting cells, which prime T-lymphocytes to produce Th2 cytokines. Two distinct lineages of dendritic cells (DC) have been described in humans, DC1 and DC2, according to their ability to induce naive T-cell differentiation to Th1 and Th2 effector cells, respectively. We have used multicolor microfluorometry to enumerate DC1 and DC2 in the peripheral blood of normal donors. G-CSF treatment with 10 to 16 ...
The cytokine Granulocyte Colony Stimulating Factor (G-CSF) treatment significantly improves the quality of life among patients with severe chronic neutropenia [Jones et al. JAMA 270: 1132-1133 (1993)]. The G-CSF is a potent endogenous trigger for the release of neutrophils from bone marrow stores and for their activation for enhanced antimicrobial activity. G-CSF has been widely evaluated in various pre-clinical models of acute illness, with generally promising results [Marshall J.C. Shock 24: 120-9 (2005)]. Due to its proven efficacy during chemotherapy cycles, the G-CSF is an important biopharmaceutical drug used in oncology. G-CSF has been cloned and expressed in various types of cells, e.g. microbial cells [Souza L.M. Science 232: 61-65 (1986); Hu Z.Y. et al. Zhongguo Shenghua Yaowu Zazhi (1999), 20: 55-57], yeast cells [Lasnik M.A. et al. Biotechnol. Bioeng. 81: 768-774 (2003); Lee S.M. et al. Korean patent KR 160934 BI 19981116], rice cells [Hong et al. Protein Expr Purif. Epub ahead of ...
Objective: To observe the efficacy and safety between Pegfilgrastim (PEG-rhG-CSF) and Recombinant human granulocyte colony stimulating factor (rhG-CSF) in hematological malignancy after allogeneic hematopoietic stem cell transplantation (allo-HSCT) . Methods: 157 patients after allo-HSCT were enrolled in this study from June 2015 to November 2016. Two agents of G-CSF were used to stimulate hematopoietic recovery after transplantation. There were 65 cases in PEG-rhG-CSF and 92 cases in rhG-CSF groups. Patients in PEG-rhG-CSF group were given a single subcutaneous dose of 6 mg on the first day and +8 d, while cases in rhG-CSF group were given in dose of 5 μg·kg(-1)·d(-1) by subcutaneous injection from +1 d continuing to neutrophils more than 1 ...
Granulocyte colony-stimulating factor (G-CSF) has been utilized to treat neutropenia in various clinical settings. Although clearly beneficial, there are concerns that the chronic use of G-CSF in certain conditions increases the risk of myelodysplastic syndrome (MDS) and/or acute myeloid leukemia (AML). The most striking example is in severe congenital neutropenia (SCN). SCN patients develop MDS/AML at a high rate that is directly correlated to the cumulative lifetime dosage of G-CSF. MDS and AML that arise in these settings are commonly associated with chromosomal deletions. We have demonstrated in this study that chronic G-CSF treatment in mice results in expansion of the hematopoietic stem cell population. In addition, primitive hematopoietic progenitors from G-CSF-treated mice show evidence of DNA damage as demonstrated by an increase in double strand breaks and recurrent chromosomal deletions. Concurrent treatment with genistein, a natural soy isoflavone, limits DNA damage in this ...
In 1980, Espey proposed a famous hypothesis that mammalian ovulation is comparable to an inflammatory reaction and many researches have proved the validity of
A stable granulocyte colony-stimulating factor-containing formulation comprising a granulocyte colony-stimulating factor and at least one pharmaceutically acceptable surfactant in an amount of 1 part by weight or less per part by weight of the granulocyte colony-stimulating factor and having a pH of 7 or less.
Granulocyte colony stimulating factor is used in the treatment of infections after chemotherapy.get complete information about granulocyte colony stimulating factor including usage, side effects, drug interaction, expert advice along with medicines associated with granulocyte colony stimulating factor at 1mg.com
Pegfilgrastim is a sustained-duration form of filgrastim, a recombinant methionyl form of human granulocyte colony-stimulating factor (G-CSF), to which a 20 ...
Clinical data regarding the use of colony-stimulating factors for the treatment of acute myeloid leukemia (AML) are conflicting because of varying study conditions. Interpretation of data is affected by differences in patients ages, induction regimens, the timing of growth factor administration, the presence of marrow hypoplasia, disease states, differences in the products used, and statistical endpoints. Most trials of granulocyte colony-stimulating factor (G-CSF) and yeast-derived granulocyte- macrophage colony-stimulating factor (GM-CSF) have demonstrated a significant shortening of neutrophil recovery time and a trend toward higher rates of complete remission. Several studies have demonstrated a significant reduction in the rates of morbidity or early mortality with G-CSF or GM-CSF. In vitro data support the concept of enhancing antimicrobial activity with macrophage colony-stimulating factor or GM-CSF. The safety and potential benefit of these cytokines suggest that cytokines should be ...
Gentaur molecular products has all kinds of products like :search , GenWay \ Granulocyte Colony Stimulating Factor Human - G-CSF \ 10-271-82083 for more molecular products just contact us
Among the entire cohort, the probability of disease-free survival (DFS) and overall survival (OS) at three years was 44% (95%CI: 39%-49%) and 52% (95%CI: 46%-57%), respectively. There was a significant difference in the probability of DFS at three years among the four groups in univariate analysis (P=0.001) (Figure 1E). The probability of DFS at three years was significantly better in the TBI≥10Gy+Ara-C/G-CSF+CY group compared with the TBI≥10Gy+Ara-C+CY group (P=0.02), the TBI≥10Gy+other group (P=0.002) and TBI,10Gy+other or non-TBI group (P=0.006). Multivariate analysis showed significantly decreased rates of treatment failure in the TBI≥10Gy+Ara-C/G-CSF+CY group compared with the TBI≥10Gy+Ara-C+CY group (P=0.01) (Table 2). In univariate analysis, there was a significant difference in the probability of OS at three years among the four groups (P=0.001) (Figure 1F). Multivariate analysis showed significantly decreased overall mortality in the TBI≥10Gy+Ara-C/G-CSF+CY group compared ...
When the donor cannot be matched to a patient with bone marrow dysfunction, the donor hematopoietic stem cells may attack the host in a process called graft-versus-host disease (GVHD). DAveni et al. show that when human donors were administered granulocyte colony-stimulating factor (G-CSF) prior to collection of peripheral blood stem cells (referred to as G-CSF-mobilized stem cells), the collected cells included a previously uncharacterized population of immunosuppressive CD34+ cells that had characteristics similar to mature monocytes. In coculture experiments with these cells isolated from G-CSF-mobilized stem cells from humans or mice, the CD34+ monocytes inhibited the proliferation of activated T cells. Further experiments with the mouse CD34+ monocytes revealed that the inhibitory effect on T cells depended on interferon-γ produced by the T cells, cell-cell contact, and production of nitric oxide (NO) by the CD34+ monocytes and not only prevented proliferation but induced apoptosis of the ...
Abstract. Within hematopoiesis, C/EBP is expressed only in myeloid cells, and PU.1 is expressed mainly in myeloid and B-lymphoid cells. C/EBP-deficient mice
Thank you for your interest in spreading the word on Stroke.. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. ...
in Human Reproduction (2013), 28(2), 406-13. BACKGROUND: Previous experiments have shown that granulocyte colony-stimulating factor (G-CSF), quantified in the follicular fluid (FF) of individual oocytes, correlates with the potential for an ongoing ... [more ▼]. BACKGROUND: Previous experiments have shown that granulocyte colony-stimulating factor (G-CSF), quantified in the follicular fluid (FF) of individual oocytes, correlates with the potential for an ongoing pregnancy of the corresponding fertilized oocytes among selected transferred embryos. Here we present a proof of concept study aimed at evaluating the impact of including FF G-CSF quantification in the embryo transfer decisions. METHODS: FF G-CSF was quantified with the Luminex XMap technology in 523 individual FF samples corresponding to 116 fresh transferred embryos, 275 frozen embryos and 131 destroyed embryos from 78 patients undergoing ICSI. RESULTS: Follicular G-CSF was highly predictive of subsequent implantation. The receiving ...
Learn about NEUPOGEN® (filgrastim) co-pay assistance programs that could help to reduce the cost of NEUPOGEN® (filgrastim) prescriptions for eligible patients.
Granulocyte colony-stimulating factor (G-CSF), encoded by the CSF3 gene in humans, is a glycoprotein, growth factor, and cytokine that controls the production, differentiation, and function of granulocytes. G-CSF stimulates the production of granulocytes from stem cells in bone marrow and their subsequent release into the circulatory system. G-CSF is expressed in endothelial cells, macrophages, and several other types of immune cells. G-CSF also regulates the differentiation and propagation of neutrophil precursors using a variety of pathways mediated by kinases such as JAK, STAT, MAPK, PI3K, and protein kinase B. Recombinant G-CSF is used in therapy for some cancer patients to assist in recovery from neutropenia.. ...
In recent years, there has been a large increase in the development of biological-based therapeutics, known as biologics, to treat a myriad of diseases. In 2015, biologics comprised 20% of the pharma market, and most analysts agree that this trend will continue to increase in the years to come.1 Biologic drugs generally are proteins, antibodies, or modified forms of biomolecules, such as an antibody conjugated to a small, organic molecule. One protein that is used in biologics is filgrastim. Filgrastim is a recombinant form of human granulocyte colony stimulating factor (GCSF) produced in Escherichia coli bacteria. Filgrastim is used to treat neutropenia, a disease characterized by an abnormally low concentration of neutrophils (white blood cells) in the blood.2. Since filgrastim is used in different biologics, it is crucial for the purity of filgrastim to be known. The main impurity present in many formulations of biologics that contain filgrastim are oxidized variants of the protein. ...